Drug intelligence / Profile preview

meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

Development stage: Approved
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is a quadrivalent conjugate vaccine used for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. The vaccine contains capsular polysaccharides from each of these four serogroups individually conjugated to the non-toxic mutant diphtheria protein carrier CRM197. This conjugation enhances the immune response by promoting T-cell dependent immunity and immunological memory. It does not protect against infections caused by N. meningitidis serogroup B or other pathogens[1][2][3][5]. The primary indication is prevention of invasive meningococcal disease in individuals aged 2 months through 55 years[1][2][9].

Brand names: Menveo
Other names: meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccineMenACWY-CRM

Targets

Neuraminidase

Beyond the preview

Go deeper on meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine.

Explore the full profile